Originally published by our sister publication Infectious Disease Special Edition
Remdesivir (Veklury, Gilead) appears to reduce the risk for certain long COVID-19 symptoms in people who were hospitalized for COVID-19, according to data presented at CROI 2024.
To understand remdesivir’s potential effect on the risk for long COVID, Gilead researchers analyzed HealthVerity data from 52,006 patients. They found using remdesivir, a nucleotide analog prodrug, was associated with a 10% lower risk